PATENT CLAIM ANALYSIS

Application Number: 15899716
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-10
Patent Classification: ["435", "325000"]

Abstract:
The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErhB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying au ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.

Claim (Index 27):
The method of  claim 16 , wherein the method comprises pre-treatment of the cells by irradiation, preferably \u03b3-irradiation.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 88.0
- Lexical Diversity: 2.41379
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15319660', '13821491', '15726943', '14928794', '15269731']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6363990281407883
- 35 USC 102 Novelty (BERT): 0.608810016263956
- Combined Prediction Score: 0.6336401269531051
- Mean Citation Score: 423.66853
- Max Citation Score: 786.81683
- Similarity Product: 449.9337019911724

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test